Handok
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Handok is a Korean pharmaceutical company that makes and distributes prescription medicines, medical devices, and health-functional foods, products used by patients and healthcare providers across South Korea.
Its portfolio includes branded medicines for conditions such as diabetes alongside consumer health products. Listed on KOSPI, South Korea's main stock exchange, the company operates across multiple business lines, including a property-leasing segment alongside its core pharmaceutical activities.
Summary is AI-generated and may contain errors · figures from DART filings
Handok maintains a manufacturing plant in Eumseong County and a dedicated research institute in Seoul's Magok district, giving it both production and R&D operations within Korea.
Handok in five facts
What does Handok do?
Handok is a Korean pharmaceutical company that makes and distributes prescription medicines, medical devices, and health-functional foods, products used by patients and healthcare providers across South Korea.
Where is Handok listed and in which sector?
Handok (Korean name: 한독) trades under KRX code 002390 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Handok?
Its market capitalisation was US$88.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Handok's latest annual revenue and operating profit?
For fiscal year 2025, Handok reported revenue of US$403.9M, operating profit of US$2.5M and a net loss of US$1.7M, per its annual report on DART (data retrieved from DART on 2026-09-06). Revenue was up 5.5% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-06
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Grant of stock optionsSep 17
- [Amended] Grant of stock optionsSep 17
- [Amended] Report on large shareholdings (5% rule) (standard)Sep 10
- [Amended] Report on large shareholdings (5% rule) (standard)Sep 10
- Report on large shareholdings (5% rule) (standard)Sep 10
- Operating results (preliminary) (fair disclosure)
Handok filed provisional (unaudited) separate results for Q2 2026: revenue of US$96.5M (+9.44% year on year), operating profit of US$1.85M (from a loss a year earlier) and a net loss of US$5.41M (from a profit a year earlier).
Earnings · Jul 30 - Operating results (preliminary) (fair disclosure)
Handok filed provisional (unaudited) separate results for Q1 2026: revenue of US$89.2M (+11.05% year on year), operating profit of US$140K (from a loss a year earlier) and a net loss of US$2.77M.
Earnings · Apr 30 - [Amended] Operating results (preliminary) (fair disclosure)
Handok updated its previously filed provisional (unaudited) separate results for Q4 2025: revenue of US$92.7M (+13.64% year on year), operating profit of US$2.87M (from a loss a year earlier) and net income of US$9.34M (from a loss a year earlier).
Earnings · Mar 10 · 2 versions - Cash/in-kind dividend decision
Handok declared a cash dividend of US$0.14 per share.
Dividend · Feb 10 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Handok reported consolidated results for FY2025: revenue of US$367M (+5.5% year on year), operating profit of US$2.26M (+511.2% year on year) and a net loss of US$1.53M.
Earnings · Feb 10